11-eicosenoic acid | 2462-94-4

• 物质功能分类: 分析化学 - 食品安全 - 脂肪酸、脂肪酸甲酯
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 11-eicosenoic acid
• 英文别名: 11-eicosaenoic acid；eicos-11-enoic acid；11-eicosanoic acid；eicosenoic acid；Eicos-11-ensaeure；ω11-eicosanoic acid；icos-11-enoic acid
• CAS: 2462-94-4
• 化学式: C₂₀H₃₈O₂
• mdl: MFCD00010506
• 分子量: 310.521
• InChiKey: BITHHVVYSMSWAG-UHFFFAOYSA-N

物化性质

• 熔点：
  47-49 °C
• 沸点：
  426.3±14.0 °C(Predicted)
• 密度：
  0.895±0.06 g/cm3(Predicted)
• 碰撞截面：
  184.1 Ų [M-H]-; 183.3 Ų [M-H]-; 187.4 Ų [M+Na]+

计算性质

• 辛醇/水分配系数(LogP)：
  7.6
• 重原子数：
  22
• 可旋转键数：
  17
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.85
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  11-eicosenoic acid 在 [1,3-bis(2,4,5-Me₃Ph)-2-imidazolidinylidene]Ru=CHPh(PCy₃)Cl₂ 、 硫酸 作用下， 反应 24.0h， 生成 1,22-docos-11-enedioic acid dimethyl ester
  参考文献：
  名称：

  不饱和脂肪酸的复分解：长链不饱和α，ω-二羧酸的合成

  摘要：

  AbstractThe self‐metathesis of readily available monounsaturated FA has the potential of being an important pathway for the synthesis of symmetrical long‐chain unsaturated‐α,ω‐dicarboxylic acids (C18−C26). Previous studies on the self‐metathesis of monounsaturated FA esters using ruthenium catalysts in solution, however, suffered from low conversions as a result of the thermodynamic control of the reaction. We have found that the second‐generation Grubbs catalyst can effectively catalyze the solvent‐free self‐metathesis of monounsaturated FA of varying purity (from 90 to 99%) to afford two important products—monounsaturated dicarboxylic acids and hydrocarbons—in very high molar conversions (>80%). This solvent‐free self‐metathesis reaction also works for monounsaturated FA containing additional functional groups. Reactions were conducted at catalyst loadings as low as 0.005 mol%, and turnover numbers as high as 10,800 could be obtained. This discovery represents an attractive approach to the large‐scale production of useful monounsaturated‐α,ω‐dicarboxylic acids and long‐chain unsaturated hydrocarbons by means of this solvent‐free ruthenium‐catalyzed self‐metathesis of readily available monounsaturated FA.

  DOI：

  10.1007/s11746-006-1249-0
• 作为产物：
  描述：

  13-二十二炔酸 在 氢氧化钾 作用下， 生成 11-eicosenoic acid
  参考文献：
  名称：

  Bodenstein, Chemische Berichte, 1894, vol. 27, p. 3398

  摘要：

  DOI：

文献信息

• [EN] LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS<br/>[FR] PROMÉDICAMENTS LIPIDIQUES ORIENTANT VERS LE SYSTÈME LYMPHATIQUE
  申请人：ARIYA THERAPEUTICS INC

  公开号：WO2019046491A1

  公开（公告）日：2019-03-07

  The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a provided lipid prodrug or a pharmaceutical composition thereof.

  本发明提供了淋巴系统定向脂质前药，其制药组合物，制备这种前药和组合物的方法，以及改善作为脂质前药一部分的治疗剂的生物利用度或其他性质的方法。本发明还提供了治疗疾病、紊乱或症状的方法，包括向需要的患者施用所提供的脂质前药或其制药组合物。
• Method of producing dicarboxylic acids
  申请人：The United States of America as represented by the Secretary of Agriculture

  公开号：US07534917B1

  公开（公告）日：2009-05-19

  A method of producing dicarboxylic acids (e.g., α,ω dicarboxylic acids) by reacting a compound having a terminal COOH (e.g., unsaturated fatty acid such as oleic acid) and containing at least one carbon-carbon double bond with a second generation Grubbs catalyst in the absence of solvent to produce dicarboxylic acids. The method is conducted in an inert atmosphere (e.g., argon, nitrogen). The process also works well with mixed unsaturated fatty acids obtained from soybean, rapeseed, tall, and linseed oils.

  一种生产二羧酸（例如，α,ω-二羧酸）的方法，通过将具有末端COOH的化合物（例如，不饱和脂肪酸如油酸）与至少含有一个碳-碳双键的第二代Grubbs催化剂在无溶剂的情况下反应，以产生二羧酸。该方法在惰性气氛（例如，氩气、氮气）中进行。此过程也适用于从大豆、油菜籽、海藻和亚麻籽油中获得的混合不饱和脂肪酸。
• [EN] CELLULAR SIGNALLING INHIBITORS, THEIR FORMULATIONS AND METHODS THEREOF<br/>[FR] INHIBITEURS DE SIGNALISATION CELLULAIRE, LEURS FORMULES ET LEURS PROCÉDÉS
  申请人：INVICTUS ONCOLOGY PVT LTD

  公开号：WO2017137958A1

  公开（公告）日：2017-08-17

  The present disclosure relates generally to Cellular Signalling inhibitors of compound of Formula (I), compositions and formulations comprising the same, methods, processes, and uses thereof. In particular, the present disclosure provides CSF-1R inhibitors demonstrating sustained inhibition of CSF/CSF1R signalling pathway with decreased toxicity. The present disclosure also provides supramolecular combinatorial therapeutics, wherein a CSF-1R inhibitor is combined with one or more of a chemotherapeutic agent, a kinase inhibitor, and an immunoregulator, each of which is optionally conjugated with a lipid. The present disclosure also provides a method for treating cancer, allergy, Systemic lupus erythematosus, nephritis, Chronic Obstructive Pulmonary Disease, and abnormal macrophage functions or any combinations thereof.

  本公开涉及一般细胞信号传导抑制剂，涉及式(I)的化合物、包含该化合物的组合物和制剂、以及它们的方法、过程和使用。特别是，本公开提供了CSF-1R抑制剂，它们表现出对CSF/CSF1R信号通路的持续抑制，并且毒性降低。本公开还提供了超分子组合疗法，其中CSF-1R抑制剂与一个或多个化疗剂、激酶抑制剂和免疫调节剂结合，其中每个可选地与脂质偶联。本公开还提供了一种治疗癌症、过敏、系统性红斑狼疮、肾炎、慢性阻塞性肺病和异常巨噬细胞功能或其任何组合的方法。
• Compounds And Compositions for the Treatment of Ocular Disorders
  申请人：Graybug Vision, Inc.

  公开号：US20170080092A1

  公开（公告）日：2017-03-23

  The disclosure describes prodrugs and derivatives of prostaglandins, carbonic anhydrase inhibitors, kinase inhibitors, beta-adrenergic receptor antagonists and other drugs, as well as controlled delivery formulations containing such prodrugs and derivatives, for the treatment of ocular disorders.

  该披露描述了前药和前列腺素的衍生物、碳酸酐酶抑制剂、激酶抑制剂、β-肾上腺素受体拮抗剂和其他药物，以及含有这些前药和衍生物的受控释放配方，用于治疗眼部疾病。
• [EN] DRUGS AND COMPOSITIONS FOR OCULAR DELIVERY<br/>[FR] MÉDICAMENTS ET COMPOSITIONS À ADMINISTRER PAR VOIE OCULAIRE
  申请人：GRAYBUG VISION INC

  公开号：WO2019118924A1

  公开（公告）日：2019-06-20

  New prodrugs of therapeutically active compounds, including oligomeric prodrugs of ethacrynic acid, and compositions to treat medical disorders, for example glaucoma, a disorder or abnormality related to an increase in intraocular pressure (IOP), a disorder requiring neuroprotection, age-related macular degeneration, or diabetic retinopathy. Also a method for the controlled administration of timolol to a patient in need thereof, such as a human, comprising administering a prodrug of timolol in a microparticle in vivo, wherein the timolol prodrug containing microparticle exhibits in vitro drug release kinetics in an aqueous solution at a pH between 6-8 at body temperature of a substantially consistent release of at least 60% timolol itself by molar ratio to the prodrug of timolol or an intermediate metabolite thereof over at least 100 days.

  新的治疗活性化合物的前药，包括乙丙酸前药的寡聚体前药，以及用于治疗医学障碍的组合物，例如青光眼，一种与眼内压增高相关的障碍或异常，需要神经保护的障碍，年龄相关性黄斑变性，或糖尿病视网膜病变。还提供了一种用于对需要的患者，如人类，进行季洛尔控制给药的方法，包括在体内给予季洛尔的前药微粒，其中季洛尔前药含有微粒体外药物释放动力学，在体温下在pH为6-8的水溶液中，以季洛尔本身至少60%的摩尔比例稳定释放至少100天的季洛尔前药或其中间代谢物。